Addex Therapeutics Research Highlights mGlu7 Modulation for Sleep Regulation

Addex Therapeutics announced the publication of research that explores the therapeutic potential of modulating the metabotropic glutamate receptor 7 (mGlu7) for the regulation of sleep and wakefulness. The findings, published in the Proceedings of the National Academy of Sciences (PNAS), shed light on the receptor's role in the balance between REM sleep and wakefulness.

The research suggests that targeting mGlu7 could offer a novel approach to treating sleep disorders. By influencing the activity of this specific receptor, it may be possible to improve sleep quality and address conditions such as insomnia. Addex Therapeutics is investigating the implications of these findings for patient care.

Addex Therapeutics has been developing compounds designed to modulate the mGlu7 receptor. This targeted approach aims to provide a more precise treatment option for patients suffering from sleep-related conditions, potentially offering an alternative to current therapies that may have broader side effects.

The investigation into mGlu7 modulation aligns with broader efforts in neuroscience to understand and treat central nervous system disorders. Addex Therapeutics' focus on this area positions the company to potentially contribute significant advancements in the field of sleep medicine.